logo-loader

Algernon Pharmaceuticals receives ethics approval as they begin clinical trials for Ifenprodil

Published: 19:02 25 Jun 2020 EDT

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling to announce the company has received ethics approval from a central institutional review board for U.S. study sites for its multinational Phase 2b/3 human study of Ifenprodil for COVID-19.

Moreau explains what that means going forward and he also updated the situation in South Korea and the good news from that country when it comes to the coronavirus.

Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough...

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to announce a significant agreement regarding the company's drug, Ifenprodil with U.S. Based Seyltx. Originally discovered in Japan and not utilized in the US or Europe, Ifenprodil was initially developed to...

17 hours, 24 minutes ago